D.E. Shaw & Co
AGL icon

D.E. Shaw & Co’s Agilon Health AGL Stock Holding History

D.E. Shaw & Co’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.8M Sell
390,149
-352,069
-47% -$23.1M 0.02% 850
2026
Q1 		$5.87M Sell
742,218
-70,235
-9% -$1.14M ﹤0.01% 2062
2025
Q4 		$14M Buy
812,453
+412,698
+103% +$8M 0.01% 1476
2025
Q3 		$10.3M Buy
399,755
+342,717
+601% +$12.9M 0.01% 1660
2025
Q2 		$3.28M Buy
57,038
+17,494
+44% +$1.4M ﹤0.01% 2357
2025
Q1 		$4.28M Buy
39,544
+24,773
+168% +$2.16M ﹤0.01% 2008
2024
Q4 		$702K Buy
14,771
+80
+0.5% +$4.84K ﹤0.01% 3419
2024
Q3 		$1.44M Buy
14,691
+7,432
+102% +$960K ﹤0.01% 2970
2024
Q2 		$1.19M Buy
7,259
+6,587
+980% +$938K ﹤0.01% 3075
2024
Q1 		$102K Buy
+672
New +$112K ﹤0.01% 4006
2022
Q4 		– Sell
-1,217
Closed -$713K – 4833
2022
Q3 		$713K Buy
+1,217
New +$729K ﹤0.01% 3823
2021
Q4 		– Sell
-14,039
Closed -$9.2M – 5353
2021
Q3 		$9.2M Buy
14,039
+5,945
+73% +$5.08M 0.01% 1574
2021
Q2 		$8.21M Buy
+8,094
New +$7.09M 0.01% 1664

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NPCM
North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

D.E. Shaw & Co's AGL Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Agilon Health (AGL) stake by 47% in Q2 2026, selling an estimated $23.1M and leaving 390,149 shares worth $41.8M. The position accounts for 0.02% of the portfolio, ranked #850.

D.E. Shaw & Co first reported a position in AGL in Q2 2021 and has held it in 13 quarters since. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

  • D.E. Shaw & Co held 390,149 shares of Agilon Health worth $41.8M as of Q2 2026.
  • D.E. Shaw & Co sold 352,069 Agilon Health shares in Q2 2026, an estimated $23.1M.
  • Agilon Health made up 0.02% of D.E. Shaw & Co's portfolio in Q2 2026, its #850 holding.
  • D.E. Shaw & Co first reported a position in Agilon Health in Q2 2021 and has held it in 13 quarters since.
  • 179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.